Insulin Degludec in Type 1 Diabetes
Open Access
- 17 February 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (3), 661-665
- https://doi.org/10.2337/dc10-1925
Abstract
OBJECTIVE: Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m2) received subcutaneous injections of IDeg(A) (600 μmol/L; n = 59), IDeg(B) (900 μmol/L; n = 60), or insulin glargine (IGlar; n = 59), all given once daily in the evening. Insulin aspart was administered at mealtimes. RESULTS: At 16 weeks, mean A1C was comparable for IDeg(A) (7.8 ± 0.8%), IDeg(B) (8.0 ± 1.0%), and IGlar (7.6 ± 0.8%), as was FPG (8.3 ± 4.0, 8.3 ± 2.8, and 8.9 ± 3.5 mmol/L, respectively). Estimated mean rates of confirmed hypoglycemia were 28% lower for IDeg(A) compared with IGlar (rate ratio [RR]: 0.72 [95% CI 0.52–1.00]) and 10% lower for IDeg(B) compared with IGlar (RR: 0.90 [0.65–1.24]); rates of nocturnal hypoglycemia were 58% lower for IDeg(A) (RR: 0.42 [0.25–0.69]) and 29% lower for IDeg(B) (RR: 0.71 [0.44–1.16]). Mean total daily insulin dose was similar to baseline. The frequency and pattern of adverse events was similar between insulin treatments. CONCLUSIONS: In this clinical exploratory phase 2 trial in people with type 1 diabetes, IDeg is safe and well tolerated and provides comparable glycemic control to IGlar at similar doses, with reduced rates of hypoglycemia.This publication has 17 references indexed in Scilit:
- Comment on: Tikhonenko et al. (2010) Remodeling of Retinal Fatty Acids in an Animal Model of Diabetes: A Decrease in Long-Chain Polyunsaturated Fatty Acids Is Associated with a Decrease in Fatty Acid Elongases Elovl2 and Elovl4. Diabetes;59:219–227Diabetes, 2010
- Nocturnal hypoglycaemia in type 1 diabetes--frequency and predictive factorsQJM: An International Journal of Medicine, 2009
- Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 DiabetesDiabetes Care, 2009
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Long‐term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat‐to‐target basal–bolus regimen with insulin aspart at meals: a 2‐year, randomized, controlled trialDiabetic Medicine, 2008
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2005
- Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetesCurrent Medical Research and Opinion, 2005
- Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based studyDiabetic Medicine, 2005
- Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies—what method should we use?Diabetic Medicine, 2004
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993